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Abstract 
Background: The performance of different malaria rapid diagnostic tests (RDT) may be influenced by transmission 
intensity and by the length of time each test requires to become negative after treatment and patient’s recovery.
Methods: Results of three RDTs (two HRP2 and one pLDH antigen‑based tests) were compared to blood smear 
microscopy (the gold standard method) in children under 5 years of age living in a high versus low malaria inten‑
sity setting in southwestern Uganda. In each setting, 212 children, who tested positive by at least one RDT and by 
microscopy, were treated with artemether‑lumefantrine. RDTs and microscopy were then repeated at fixed intervals 
to estimate each test’s time to negativity after treatment and patient recovery.
Results: In the two settings, sensitivities ranged from 98.4 to 99.2 % for the HRP2 tests and 94.7 to 96.1 % for the 
pLDH test. Specificities were 98.9 and 98.8 % for the HRP2 tests and 99.7 % for the pLDH test in the low‑transmission 
setting and 79.7, 80.7 and 93.9 %, respectively, in the high‑transmission setting. Median time to become negative was 
35–42 or more days for the HRP2 tests and 2 days for the pLDH test.
Conclusions: High transmission contexts and a long time to become negative resulted in considerably reduced spe‑
cificities for the HRP2 tests. Choice of RDT for low‑ versus high‑transmission settings should balance risks and benefits 
of over‑treatment versus missing malaria cases.
Trial registration: Registry number at ClinicalTrial.gov: NCT01325974
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Background
Diagnosis of malaria based only on clinical grounds leads 
to significant overestimates of malaria illnesses even 
when diagnosis is carried out by experienced clinicians 
[1, 2]. Misdiagnosis is problematic for multiple reasons: 
it exposes patients to unnecessary side-effects of drugs 
and to the risk of overlooking potentially fatal conditions, 
such as pneumonia [3] or diseases of epidemic poten-
tial (i.e., Lassa fever or Ebola), and it contributes to the 
emergence of resistance to anti-malarials [4]. For these 
reasons the World Health Organization (WHO) recom-
mends that every clinical suspicion of malaria should be 
confirmed by either microscopy or rapid diagnostic test 
(RDT) prior to initiating treatment [5]. Today RDTs have 
become the method of choice in many contexts since 
they allow an easy-to-use biological confirmation that 
can be performed in low-resource settings where good 
quality microscopy cannot be maintained, such as remote 
health centres or at community level.
The number of different RDTs on the market has 
increased considerably over the past few years. In 2008, 
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WHO launched the Product Testing Programme, which 
evaluates performance of commercialized malaria RDTs 
against a standardized panel of laboratory-prepared 
specimens. This programme, which has already com-
pleted its fifth round of testing, allows for product com-
parisons, encourages producers to improve their tests 
and, in the long run, promotes product quality. WHO 
acknowledges however, that its results cannot predict 
test performance in the field, where other factors such 
as malaria antigen persistence in the blood and malaria 
endemicity can influence RDT performance [6].
Most malaria RDTs are designed to detect a single par-
asite antigen, the histidine-rich protein 2 (HRP2) or the 
Plasmodium lactate dehydrogenase (pLDH), while others 
are designed to detect both antigens in a single test.
HRP2 is a protein produced only by the Plasmodium 
falciparum species; detection of this protein can there-
fore confirm only P. falciparum infections. Many of the 
HRP2-based RDTs show very high scores in the WHO 
evaluation [7]. For instance, the CareStart HRP2 was 
reported to have a 98.7 % detection rate (a proxy meas-
urement of sensitivity) and a false positive rate (proxy of 
the inverse of specificity) of 2.4 %. However, these HRP2-
based tests performed more poorly in the field, particu-
larly in terms of their specificity, due primarily to the 
slow elimination of the HRP2 antigen from the blood-
stream. This persistence of the HRP2 antigen means 
that patients continue to test positive with HRP2-based 
RDTs long after the patient was treated and the parasites 
eliminated. During this period, these tests therefore can-
not distinguish between lingering positivity and de novo 
infection. This phenomenon is well documented in high-
transmission areas where patients frequently experience 
repeated malaria infections and treatments [8–10]. How-
ever, little is known about field performance of these tests 
in low-transmission areas where malaria infections are 
rare.
The pLDH is a parasite protein produced by all Plas-
modium species; RDTs based on this antigen can there-
fore detect all Plasmodium species but are generally less 
sensitive than HRP2 tests. Their main advantage is that 
pLDH is rapidly eliminated from the blood stream after 
treatment, and therefore pLDH-based RDTs returns a 
negative result within a few days after treatment.
The objective of this study was to explore whether and 
how much three malaria RDTs vary, in terms of sensi-
tivity, specificity and time to become negative, based on 
transmission setting. The three RDTs chosen were among 
the highest scoring tests in the WHO Round 3 malaria 
test performance evaluation [7] (two HPR2 RDTs and 
one pLDH RDT). Tests were assessed in parallel in two 
settings: one with high malaria transmission, the other 
with low transmission, in southwestern Uganda.
Methods
Study settings
The study was conducted from September 2011 to Janu-
ary 2013 within the Greater Mbarara district at two loca-
tions: Mbarara municipality, where malaria prevalence in 
children below 5 years of age was relatively low (3–4 %), 
and Kazo, located 80 km north of Mbarara municipality, 
where malaria prevalence was ten-fold higher (40–60 %) 
as reported in a previous study [11]. In Mbarara munici-
pality the study was hosted at the Kakiika Health Centre; 
seven other health structures located within or just out-
side the Mbarara municipality also participated by pro-
viding eligible patients. In Kazo the study was hosted at 
the sole health centre present in the sub-county.
The Greater Mbarara district is located between 130 m 
and 1500 m altitude above sea level and its vegetation is 
a mixture of bush and short grass. The climate is tropical 
with a bi-modal rainfall pattern averaging 1200 mm per 
annum. The rainfall season falls between mid-August to 
December and mid-February to May. Malaria transmis-
sion is on-going throughout the year, with two seasonal 
peaks occurring 2 months after the periods of heavy rain-
fall. Plasmodium falciparum is almost the only species 
documented. Malaria constitutes one of the major causes 
of illness in the area.
Sample size
The sample size was calculated to respond to the main 
study objective, the time to become negative of RDTs, 
and was based on the expected proportions of RDTs that 
remained positive at each follow-up day. It was estimated 
that 184 patients were needed to achieve the accuracy of 
8 % around a proportion of 50 % positive RDTs and of 3 % 
around proportions of 5 or 95  %. By expecting 15  % of 
patients not being positive for all RDTs, lost to follow up 
or excluded from the primary analysis, 212 patients were 
estimated to be included in each study site.
For the sensitivity analysis all patients with a positive 
microscopy with a P. falciparum infection were included 
until the sample size for the time to become negative 
analysis was achieved. For the specificity analysis, the 
number of patients with a negative microscopy depended 
of the intensity of malaria transmission. A negative/posi-
tive microscopy ratio of around 1:1 and of at least 5:1 
was expected in the high and low transmission settings 
respectively.
Patient recruitment and follow‑up
The study recruited consecutively all children who pre-
sented to any of the participating health centres, were 
under 5  years of age, weighed 5  kg or more, and either 
had fever ≥37.5 °C or whose parent reported fever within 
the previous 2  days. Blood samples obtained by finger 
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prick from children whose parent or guardian provided 
written consent were tested in parallel at the correspond-
ing study health centre with the three different RDTs and 
with microscopy. Patients recruited at this stage formed 
the population sample for the RDT performance analysis.
At each site, a sub-set of 212 children was selected 
for the time to become negative analysis. Inclusion cri-
teria were: positivity for at least one RDT, having a P. 
falciparum mono-infection (i.e., no additional species) 
confirmed by microscopy, and having not taken any anti-
malarial drug within the previous 2 weeks (as reported by 
the parent). Participants stayed with a parent or guard-
ian in an observation room of the health centre for 3 days 
(day 0–day 2) to receive a full course of artemether-lume-
fantrine (Coartem®, Novartis) under the supervision of 
study personnel. When treatment intake was completed, 
participants were sent home. During their stay at the 
health centre and at follow-up visits on a fixed schedule 
(days 2, 3, 5, 7, 14, 21, 28, 35, and 42) patients received a 
clinical check-up and malaria testing using all three RDTs 
and microscopy. If an RDT was negative at a given visit, 
that test was not repeated during subsequent visits. Fol-
low-up was discontinued as soon as all RDTs were nega-
tive, or at a maximum of 42 days.
Patients with recurrent parasitaemia during follow-
up were treated with artesunate-amodiaquine (AS–AQ 
Winthrop®, Sanofi Aventis). Patients who did not appear 
for a follow-up visit after day 3 (when they went home 
from the centre) and for whom it was not possible to 
recover any additional information were considered lost 
to follow-up.
Laboratory techniques
The following RDTs were evaluated: SD Bioline Malaria 
Antigen P.f (HRP2) (Standard Diagnostic Inc, Suwon, 
South Korea, catalogue number: 05FK50-02-4), Car-
eStart Malaria HRP2 (Pf ) (Access Bio, Somerset, USA, 
catalogue number: G0141) and CareStart Malaria pLDH 
(PAN) (Access Bio, catalogue number: G0111). RDTs 
were performed according to manufacturer’s instruc-
tions. All RDTs were read by two blinded, independent 
readers. The first reading was done at 15  min for the 
SD Bioline test and 20  min for the two CareStart tests. 
The first reader wrote the result in a paper form which 
was handed to the lab supervisor. The supervisor called 
within 5 min the second reader who wrote the result in 
a second paper form. The supervisor confronted the 
results. If results were discordant the supervisor acted as 
third tie-breaker reader. The third reading occurred typi-
cally within 10 min after the first reading. The lot number 
of each test was recorded and the storage temperature 
monitored.
For microscopy, thick and thin blood smears were pre-
pared on the same slide and stained with a 10 % Giemsa 
solution (pH 7.2) for 15  min. Reading was performed 
using a 100× magnification lens with oil immersion. Par-
asite asexual forms were counted against a threshold of 
200 white blood cells (WBC); if fewer than ten parasites 
were seen at this threshold, counting was continued until 
at least 500 WBC. Plasmodium species was confirmed 
on the thin smear. Two-hundred high-power fields were 
read before declaring a blood slide negative.
Parasite density was estimated based on a hypotheti-
cal leukocyte density of 8000 WBC/µL. The presence of 
gametocytes was recorded, although a slide with game-
tocytes but no asexual parasite forms was scored as 
negative.
Double reading of all slides was performed. Slides with 
discordant results (positive/negative or parasite density 
of second reader varying by ≥50 % compared to the first 
reader) were read by a third reader. The parasite density 
result was calculated as the mean of the first and sec-
ond readers, if not discordant, or as the mean of the two 
closest results, if a third reading was required. Blinding 
of microscopists to RDT results was ensured by assign-
ing to the slides a different laboratory code, so that only 
the laboratory supervisor could match the microscopy 
result to the patient’s identification number that was used 
for the RDT. All study microscopists had a Kappa score 
≥80 % in evaluations of microscopists conducted by the 
reference laboratory of the Shoklo Malaria Research Unit 
(Thailand) in 2010, prior to the start of this study.
Data processing and analysis
Data were double-entered and validated in a Voozanoo 
database (EpiConcept, Paris, France). Data analysis was 
carried out using Stata version 12.1 (Stata Corp, College 
Station, TX, USA).
Qualitative variables were assessed by percentages and 
95  % confidence intervals (95  % CI). Quantitative vari-
ables were described by mean and standard deviation if 
normally distributed, and by median and interquartile 
25 and 75 percentiles range (IQR), if not normally dis-
tributed. Comparison of continuous numeric variables 
was tested with Student t test if normally distributed, 
and with Mann-Whitney rank-sum test if not normally 
distributed.
Sensitivity, specificity, positive and negative predic-
tive values, and misclassification rates were estimated 
for each RDT separately, with microscopy as the gold 
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standard. All patients with P. falciparum (mono- or 
mixed species infection) were included in the analysis, 
while patients with an infection that did not include P. 
falciparum were excluded, since the HRP2 tests in the 
study detect only P. falciparum.
RDT sensitivity and specificity were defined as the pro-
portion of positive test results among the microscopy-
positive blood smears, and the proportion of negative 
tests among the negative blood smears, respectively. The 
positive and negative predictive values were defined as 
the proportion of positive blood smears among the posi-
tive tests, and of negative blood smears among the nega-
tive tests, respectively. The misclassification rate was 
defined as the proportion of erroneous results (the sum 
of false positive and false negative results) among the 
total number of tests performed.
Performance comparisons between RDTs in the same 
site, and of the same RDT among sites, were expressed 
as differences with 95  % CI. McNemar’s test was used 
to assess statistical significance in performance among 
RDTs in the same site while Fisher’s exact test was used 
to assess statistical significance in performance of the 
same RDT between sites.
Sensitivity of RDTs in three strata defined as low 
(1–1999 parasites/µL), medium (2000–199,999 para-
sites/µL) and high parasite density (200,000 parasites/µL 
or more) were also assessed and compared. For this last 
analysis, results from the two sites were combined.
The time to become negative was defined as the 1st day 
when an RDT was reported as negative. Patients with 
incomplete or incorrect intake of anti-malarial treatment 
and patients who presented recurrent parasitaemia start-
ing from day 7 (i.e., malaria microscopy was again posi-
tive) before all RDTs had become negative were excluded 
from the analysis. Patients lost to follow-up were cen-
sored at their last visit.
The probability of a test remaining positive over time 
was calculated with the Kaplan–Meier survival function. 
The same survival analysis was carried out on three strata 
according to initial parasitaemia. Strata were defined as 
low, medium and high parasite densities (same cut-off as 
for RDT performance).
Ethics, consent and permissions
The study protocol was approved by the Ethical Review 
Board of Médecins Sans Frontières, the Faculty Research 
Ethical Committee and the Institutional Review Board of 
Mbarara University of Sciences and Technology, and the 
Uganda National Council for Sciences and Technology.
All patients were recruited after a parent or guard-
ian provided written consent, and all patients received 




Recruitment in the Mbarara municipality took place 
from November 2011 until the end of January 2013, an 
extended period that reflected the area’s low malaria 
transmission, and consequently, the long time needed to 
recruit sufficient numbers of malaria-positive patients. 
Patients in high-transmission Kazo were recruited from 
September to December 2011.
A total of 4977 and 521 patients were admitted to the 
study in Mbarara and Kazo, respectively, of whom 4803 
and 459 patients were included in the RDT performance 
analysis. The reasons for exclusion are listed in (Fig.  1). 
The number of invalid tests was 121 for SD Bioline HRP2, 
three for CareStart HRP2 and one for CareStart pLDH. 
The median age of participating children in Mbarara was 
significantly lower (17 months) than in Kazo (24 months) 
(p value  <0.001) while haemoglobin level was higher in 
Mbarara than in Kazo (Table 1).
Of the 212 patients recruited at each site for evaluat-
ing each RDT in terms of time to negativity after malarial 
treatment, 14 (6.6 %) and 98 (46.2 %) patients in Mbarara 
and Kazo, respectively, were excluded from the analysis at 
some point before completion of their planned visits. The 
most common reason for exclusion was the occurrence 
of a recurrent parasitaemia during follow-up, which was 
found in eight patients (3.8 %) in Mbarara and 89 patients 
(42  %) in Kazo. Other reasons are listed in the study 
flow chart (Fig.  1). The analysis was ultimately carried 
out on a sample of 198 and 114 patients in Mbarara and 
Kazo respectively. In this participant group, the median 
age was higher in Mbarara (29.5  months) than in Kazo 
(23  months) (rank-sum test p value  =  0.003). Median 
levels of parasitaemia were 48,528 and 37,962 parasites/
µL in Mbarara and Kazo, respectively, with no significant 
difference between the two study sites (rank-sum test p 
value  =  0.573) (Table  1). The number of P. falciparum 
mono-infections, mixed and non-falciparum infections 
are listed in Table 2.
Test performance
RDT performance data in the different settings are sum-
marized in Table 3. The sensitivities of the two HRP2 tests 
ranged from 98.4 to 99.2 %, with no significant difference 
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between the two RDTs and between sites. Sensitivity of 
the pLDH test, which was 96.1  % in low-transmission 
Mbarara and 94.7  % in high-transmission Kazo, was 
significantly inferior to that of CareStart HPR2 in Mba-
rara (McNemar p value: 0.0156) and to both SD Bioline 
HRP2 and CareStart HRP2 in Kazo (McNemar p values: 
0.0005 and 0.0034, respectively). In five patients, three 
in Mbarara and two in Kazo, the microscopy was posi-
tive for P. falciparum but all three RDTs were negative. 
The parasite densities were low or moderated for four of 
these patients (110, 246, 1081 and 10,805 parasites/µL) 
and very high for one patient (282,667 parasites/µL). Spe-
cificities of all three RDTs were high in Mbarara, ranging 
from 98.8 to 99.8 %. In Kazo, the specificities were 79.7 % 
for SD Bioline HRP2 80.7  % for CareStart HPRP2 and 
93.9 % for CareStart pLDH, which were significantly infe-
rior to Mbarara, especially for the two HRP2 tests (19.2 % 
for SD Bioline HRP2 and 18.1  % for CareStart HPRP2). 
A less marked, though still significant, inferior specificity 
(5.8 %) was observed for the CareStart pLDH.
The positive predictive values of the two HRP2 tests 
were similar in Mbarara and Kazo. The negative predic-
tive value of the pLDH test was lower in Kazo (but not in 
Mbarara) compared with the HRP2 tests.
Variation in RDT performance based on parasite den-
sity stratification was similar at the two study sites (Addi-
tional file 1) and were therefore pooled from both study 
sites. The sensitivity in patients with low parasite density 
was 94.5 % for both HRP2 tests and 75.3 % for CareStart 
pLDH (McNemar’s p values <0.001 for CareStart pLDH 
versus both HRP2 tests), while the sensitivity of all three 
RDTs ranged between 98.3 and 99.7 % in the medium and 
high parasite density strata, with no difference between 
these two latter strata and among RDTs (Table  4). One 
patient with a parasite density above 200,000 parasites/
µL had a negative result with all three RDTs evaluated.
Time to become negative
The median time to become negative was 35 and 42 days 
for the SD Bioline HRP2 in Mbarara and Kazo, respec-
tively, and 2  days for the CareStart pLDH at both sites. 
For the CareStart HRP2 test, the median time could not 
be calculated because it exceeded 42 days, the maximum 
follow-up time for patients in this study (Fig. 2). For the 
same reason, it was possible to calculate the 95th percen-
tile only for the pLDH tests, which was 14 days. In both 
settings patients with higher parasitaemia at inclusion 
had a longer time to become negative (Fig.  3). Similar 
Fig. 1 Flowchart of patients participating to the study
Page 6 of 12Grandesso et al. Malar J  (2016) 15:496 
results were found in the analysis when patients with 
recurrent parasitaemia were censored at the day when 
the recurrent parasitaemia occurred (Additional file 2).
Discussion
All three RDTs evaluated in this study performed better 
in the low- than in the high-transmission setting, with 
striking differences especially regarding specificity. While 
the low specificity of the HRP2 tests (around 80 %) in the 
high-transmission setting of Kazo confirmed previous 
studies from similar epidemiological contexts, for exam-
ple, 73  % in Ghana [12] and 63  % in Tanzania [13], the 
high specificity (almost 99  %) in the low-transmission 
setting of Mbarara municipality was consistent with the 
very low false positive rate reported in the WHO Product 
Testing Programme [7].
The long-lasting HRP2 antigens, when combined with 
a high frequency of malaria infections, may lead to quasi-
persistent antigen positivity in children living in high 
malaria transmission areas. A clear demonstration of this 
situation is the high number of children (86 out of 212) 
in Kazo that experienced a recurrent malaria infection 
Table 1 Demographic and clinical characteristics of children participating in the study
$  Mann–Whitney rank-sum test p value <0.001
§  Student’s t-test p value <0.001
‡  Mann–Whitney rank-sum test p value = 0.003
£  Student’s t-test p value = 0.184
¥  Mann–Whitney rank-sum test p value = 0.573
Included in the performance analysis (N) Mbarara Kazo
4803 459
Gender
 Male (n,  %) 2493 51.9 218 47.5
 Female (n,  %) 2310 48.1 241 52.5
Age (months) (median, IQR)$ 17 10–31 24 13–36
Reported fever (n,  %) 4783 99.8 446 97.4
Temperature >37.5 °C (n,  %) 2296 47.9 233 51.0
Haemoglobin (g/dL) (mean, SD)§ 11.4 1.6 10.3 2.1
Blood smear positive for P. falciparum (n,  %) 256 5.3 262 57.1
Included in the time to become negative analysis (N) Mbarara Kazo
198 114
Gender
 Male (n,  %) 95 48.0 51 44.7
 Female (n,  %) 103 52.0 63 55.3
Age (months) (median, range)‡ 29.5 15–44 23 12–33
Reported fever (n,  %) 197 99.5 111 97.4
Temperature >37.5 °C (n,  %) 142 71.7 74 69.2
Haemoglobin (g/dL) (mean, SD)£ 10.4 1.9 10.1 2.0
P. falciparum asexual forms parasites per µL (median, IQR)¥ 48,528 8473–132,000 37,962 6545–125,333
Table 2 Plasmodium species in  patients included in  the 
RDT performance analysis by study site
Mbarara Kazo
n % n %
Total patients positive  
(any Plasmodium species)
285 100.0 306 100.0
P. falciparum mono‑infection 260 91.2 233 76.1
Mixed P. falciparum infection 7 2.5 30 9.8
Other non‑P. falciparum mono‑infections 18 6.3 43 14.1
 P. vivax mono‑infection 2 0.7 1 0.3
 P. ovale mono‑infection 4 1.4 10 3.3
 P. malariae mono‑infection 12 4.2 32 10.5
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before clearing the HRP2 antigens of the previous one. 
This is not the case for children living in low-transmis-
sion settings, who are much less likely to have had a 
recent malaria infection.
Unlike specificity, the sensitivity of all three RDTs was 
high in both settings; however the pLDH test performed 
less well than the HRP2 tests. Sensitivity estimates con-
firm the WHO evaluations [6, 7] and are in line with pre-
vious studies [14, 15]. Only Nyunt and colleagues found 
that the sensitivity of the pLDH test was as high as an 
HRP2 test [10].
Data of this study clearly indicate that the relatively low 
sensitivity of the pLDH test was observed only at low par-
asite density. Nevertheless, this low sensitivity is highly 
problematic for public health decision makers, who typi-
cally favour deploying highly sensitive tests such as the 
HRP2 RDTs, accepting the associated risk of unnecessar-
ily treating uninfected patients over taking the risk of fail-
ing to detect malaria cases. Regarding specificity, the high 
number of false positives observed with HRP2 tests is also 
problematic, particularly in high transmission settings 
where half or more of RDTs are positive. A wrongly positive 
result may divert clinicians’ attention from other possible 
aetiologies of febrile illnesses, or may lead clinicians to mis-
trust the RDT result, diminishing their perceptions of the 
test’s usefulness. The two HPR2 tests showed much longer 
times to become negative (median of 35 to >42 days) than 
expected from most previous reports. Only one study in 
the Democratic Republic of Congo [9] reported such a long 
time to become negative, whereas others report median 
times of no longer than 21 days [6, 14, 16].
In contrast, the two-day median time of pLDH anti-
gen persistence generally seems to parallel a decline in 
the number of viable parasites during treatment [15, 17, 
18]. In some instances, however, the pLDH antigen may 
persist for longer. Nyunt and colleagues reported in their 
study in Myanmar a median time of 6 days [10]. Njama-
Meya and colleagues reported that 7 % of patients were 
still positive at 28  days. In this study no patient was 
positive beyond 21 days. The reasons for this difference 
remain unexplained.
While time to become negative did not vary substan-
tially according to the intensity of transmission, it dif-
fered based on initial parasite density: the higher the 
initial parasite density, the more time was required to 
clear parasite antigens [8]. This finding supports the 
hypothesis that the level of antigens in the bloodstream is 
proportional to parasite density [19].
The study had a number of limitations. Some negative 
microscopy results may represent real infections with a 
Fig. 2 Time to become negative for three malaria RDTs, expressed as Kaplan–Meier survival estimates, in Mbarara (low transmission setting) and in 
Kazo (high transmission setting)
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sub-microscopic parasite density. In this case, if the RDT 
was positive, results may have been wrongly classified as 
false positive instead of true positive. Considering the 
high sensitivity of HRP2 tests in low parasitaemias, this 
circumstance may have affected a higher proportion of 
HRP2 test results than pLDH results.
Double reading of all slides and the inspection of 200 
fields before scoring a blood smear as negative were per-
formed to ensure high quality results. Nevertheless, it 
may be possible that some low parasite densities went 
undetected and were therefore wrongly classified as neg-
ative [20].
The PCR molecular assay is proved to be more sensitive 
than a well performed microscopy [21] and would have 
provided more comparable results with recently pub-
lished studies [22]. Nevertheless, while the high sensitiv-
ity provided by the PCR is important in contexts where 
it is crucial to detect infections with low parasite den-
sity—e.g. in a malaria elimination programme—its added 
value in clinical diagnosis is arguable, since the clinical 
meaning of a child’s sub-microscopic infection in a high-
transmission area is still debated.
Children with recurrent parasitaemia during follow-up 
were excluded from the time to become negative analy-
sis. This choice had the consequence of reducing the size 
of the analysable patient cohort. Reduction was limited 
in the low-transmission setting (eight patients in Mba-
rara), but led to exclusion of one-third of all patients at 
the Kazo site (89 patients). The characterization of pol-
ymorphic markers to distinguish a re-infection from a 
recrudescence, a standard method in anti-malarial effi-
cacy studies, would have allowed to censor, rather than to 
exclude, these children.
The time to become negative for a given RDT was 
determined on the basis of the first negative result during 
follow-up, and assumed that any subsequent result with 
the same RDT was also negative. It may be possible that, 
in some few instances, a subsequent RDT could have been 
positive. This definition may therefore have biased esti-
mates of time to become negative towards shorter times.
Fig. 3 Time to become negative for three RDTs stratified by parasite density at patient’s admission, expressed as Kaplan–Meier survival estimates. 
Patients from Mbarara (low‑transmission setting) and Kazo (low transmission setting) are combined
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Conclusions
The ideal malaria RDT, a test that is both highly sensitive 
and highly specific in all epidemiological contexts is not yet 
available. A choice is to be made between an HPR2 test, with 
the risk of overdiagnosing malaria and thereby overlook-
ing other possible causes of fever, and using a pLDH test, 
which carries the risk of missing true malaria cases with low 
parasitaemia. Three-band RDTs, combining detection of 
both HRP2 and pLDH antigens, are also available. However 
these RDTs are not better performing than the two-band 
tests [23] and may be a source of confusion when the HRP2 
antigen is detected and not the pLDH one, or vice versa. In 
this sense an RDT detecting only pLDH with a higher sen-
sitivity than the products currently on the market would be 
the optimal solution. Meanwhile, the findings of this study 
can be used to guide health decision makers in choosing the 
most appropriate test for a given context, and to help medi-
cal practitioners interpret RDT results.
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